Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL

Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL

obr

1 year
47 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Up Next Autoplay
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Category: Non-Hodgkin Lymphoma
35 Views
ash 1 month
Analysis of Brentuximab Vedotin Plus  CHP (A+CHP) #ASH19 @OfficialUoM
Analysis of Brentuximab Vedotin Plus CHP (A+CHP) #ASH19 @OfficialUoM
Category: Non-Hodgkin Lymphoma
9 Views
ash 1 month
Follow-Up in Relapsed/Refractory MCL #ASH19
Follow-Up in Relapsed/Refractory MCL #ASH19
Category: Non-Hodgkin Lymphoma
20 Views
ash 1 month
Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering
Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering
Category: Non-Hodgkin Lymphoma
35 Views
ash 1 month
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19
Category: Non-Hodgkin Lymphoma
4 Views
ash 1 month
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
11 Views
Cancer-News 1 month
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 1 month
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
11 Views
ash 1 month
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
27 Views
Cancer-News 1 month
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
6 Views
Cancer-News 2 months